Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biogeneric Native and Polyethylene Glycol-conjugated Escherichia coli Asparaginases for Treating Children with Acute Lymphoblastic Leukemia.

Therapeutic drug monitoring·2026
Same author

Predictors of long-term outcome in open spina bifida.

Developmental medicine and child neurology·2026
Same author

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study.

The Lancet regional health. Southeast Asia·2026
Same author

Slow walking speed and risk of cardiovascular events in type 2 diabetes: a systematic review.

BJGP open·2026
Same author

Maternal vaccination service provision in London and Liverpool: Organisation, recording of vaccinations and midwife training.

Future healthcare journal·2025
Same author

Digital Information Sharing Before Consultations in General Practice: Protocol for a Scoping Review.

JMIR research protocols·2025

Related Experiment Video

Updated: Jun 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Warfarin for atrial fibrillation

Jasmeet Sidhu, Pippa Oakeshott

    The British Journal of General Practice : the Journal of the Royal College of General Practitioners
    |November 30, 2006
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
    28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
    10:46

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

    Published on: May 26, 2015

    Related Experiment Videos

    Last Updated: Jun 24, 2026

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
    28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
    10:46

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

    Published on: May 26, 2015